AGBL2 and rheumatoid arthritis: Anti-CCP3 antibodies have a potential role in the identification of CCP2+ individuals who are about to develop clinical or subclinical RA-related joint inflammation (i.e. before the ‘second hit' in RA pathogenesis occurs).